Immunic, Inc. (IMUX)
NASDAQ:IMUX
Want to see IMUX full AI Analyst Report?
IMUX Stock Chart & Stats
$1.00
-$0.01(-1.34%)
At close: 4:00 PM EST
$1.00
-$0.01(-1.34%)
Day’s Range― - ―
52-Week Range$5.06 - $15.77
Previous CloseN/A
Volume261.21K
Average Volume (3M)276.28K
Market Cap
$159.51M
Enterprise Value-$38.57M
Total Cash (Recent Filing)$186.63M
Total Debt (Recent Filing)$421.00K
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 06, 2026EPS Estimate
-1.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.98
Shares Outstanding13,621,483
10 Day Avg. Volume273,601
30 Day Avg. Volume276,284
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-12.46
Price to Sales (P/S)0.00
P/FCF Ratio-0.97
Enterprise Value/Market Cap-0.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.17K
Enterprise Value/Ebitda0.35
Forecast
1Y Price Target
$36.50Price Target Upside3550.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.53
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Data StrengthRobust Phase 2 CALLIPER signals and safety data provide a durable evidence base supporting vidofludimus calcium's differentiation in MS. Consistent favorable post-hoc outcomes and benign safety across 467 patients increase the likelihood of successful phase 3 design, regulatory engagement, and eventual commercial positioning.
Experienced Commercial LeadershipBringing a CEO with proven MS commercial launch experience materially strengthens execution risk management for late-stage development and potential commercialization. This leadership upgrade improves planning for regulatory filings, market access, and scaling commercial operations over the next several quarters.
Low Financial LeverageMinimal debt reduces fixed financial obligations and lowers bankruptcy risk, giving the company flexibility to structure financings, partnerships, or milestone-based collaborations. This capital structure trait supports sustained R&D investment and strategic optionality during late-stage programs.
Bears Say
No Commercial RevenueAs a pre-revenue biotech, Immunic lacks product-derived cash inflows, leaving commercialization contingent on clinical success and external funding. Persistent net losses mean profitability is unlikely in the 2–6 month horizon and create ongoing dependency on capital markets or partners to sustain operations.
Sustained Negative Cash FlowConsistently negative operating and free cash flow indicates material cash burn tied to R&D and trials. This creates a durable funding requirement over coming quarters, raising dilution and execution risk if capital access tightens, and constrains the firm's ability to self-fund pivotal programs.
Balance Sheet VariabilityLarge swings in equity reflect episodic financings or accounting shifts that complicate runway visibility and signal reliance on one-off capital actions. Such volatility can disrupt planning, dilute shareholders, and imply recurring financing needs until commercial revenues materialize.
Immunic News
IMUX FAQ
What was Immunic, Inc.’s price range in the past 12 months?
Immunic, Inc. lowest stock price was $5.06 and its highest was $15.77 in the past 12 months.
What is Immunic, Inc.’s market cap?
Immunic, Inc.’s market cap is $159.51M.
When is Immunic, Inc.’s upcoming earnings report date?
Immunic, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 56 days.
How were Immunic, Inc.’s earnings last quarter?
Immunic, Inc. released its earnings results on May 13, 2026. The company reported -$1.08 earnings per share for the quarter, missing the consensus estimate of -$0.688 by -$0.392.
Is Immunic, Inc. overvalued?
According to Wall Street analysts Immunic, Inc.’s price is currently Undervalued.
Does Immunic, Inc. pay dividends?
Immunic, Inc. does not currently pay dividends.
What is Immunic, Inc.’s EPS estimate?
Immunic, Inc.’s EPS estimate is -1.18.
How many shares outstanding does Immunic, Inc. have?
Immunic, Inc. has 13,621,483 shares outstanding.
What happened to Immunic, Inc.’s price movement after its last earnings report?
Immunic, Inc. reported an EPS of -$1.08 in its last earnings report, missing expectations of -$0.688. Following the earnings report the stock price went up 8.824%.
Which hedge fund is a major shareholder of Immunic, Inc.?
Currently, no hedge funds are holding shares in IMUX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$36.50 (3550.00% Upside)
$36.50 (3550.00% Upside)
Blogger Sentiment
Bullish
IMUX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 100.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
32.27%
12-Months-Change
Fundamentals
Return on Equity
-220.75%
Trailing 12-Months
Asset Growth
824.89%
Trailing 12-Months
Company Description
Immunic, Inc.
Immunic, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to pioneering selective oral immunotherapies for a range of chronic inflammatory and autoimmune conditions. Its primary investigational compound, IMU-838, has advanced to Phase 2 clinical trials, targeting relapsing-remitting multiple sclerosis (RRMS), inflammatory bowel disease (IBD), various other chronic inflammatory and autoimmune disorders, and also coronavirus disease. Additionally, the company is advancing IMU-935, which functions as an inverse agonist of RORγt, and IMU-856, designed to restore the intestinal barrier for patients afflicted with conditions like inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor-induced colitis, and other ailments affecting intestinal barrier integrity. The company's headquarters are located in New York, New York.
IMUX Stock 12 Month Forecast
Average Price Target
$36.50
▲(3550.00% Upside)
Technical Analysis
aTyr Pharma
―
vTv Therapeutics
―
NRX Pharmaceuticals
―
Equillium
―
Werewolf Therapeutics
―
Ownership Overview
6.12% Insiders
8.52% Mutual Funds
<0.01% Other Institutional Investors
81.10% Public Companies and Individual Investors